Daymark Wealth Partners LLC Buys 3,541 Shares of Johnson & Johnson (NYSE:JNJ)

Daymark Wealth Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 313,573 shares of the company's stock after acquiring an additional 3,541 shares during the period. Johnson & Johnson comprises about 1.8% of Daymark Wealth Partners LLC's investment portfolio, making the stock its 12th biggest position. Daymark Wealth Partners LLC's holdings in Johnson & Johnson were worth $52,003,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. CHICAGO TRUST Co NA raised its stake in Johnson & Johnson by 0.5% during the first quarter. CHICAGO TRUST Co NA now owns 17,890 shares of the company's stock worth $2,967,000 after acquiring an additional 93 shares in the last quarter. Range Financial Group LLC grew its holdings in shares of Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after purchasing an additional 2,529 shares during the last quarter. Portside Wealth Group LLC increased its position in shares of Johnson & Johnson by 96.8% during the 1st quarter. Portside Wealth Group LLC now owns 29,501 shares of the company's stock worth $4,893,000 after purchasing an additional 14,513 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 8.1% during the 1st quarter. Moss Adams Wealth Advisors LLC now owns 11,123 shares of the company's stock valued at $1,845,000 after purchasing an additional 830 shares during the last quarter. Finally, NewSquare Capital LLC grew its stake in Johnson & Johnson by 266.9% during the first quarter. NewSquare Capital LLC now owns 1,064 shares of the company's stock worth $176,000 after buying an additional 774 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.8%

Shares of NYSE:JNJ traded up $1.22 during mid-day trading on Tuesday, reaching $156.45. The stock had a trading volume of 6,791,151 shares, compared to its average volume of 7,934,951. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $376.43 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The firm has a 50 day simple moving average of $153.59 and a two-hundred day simple moving average of $153.67.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on JNJ. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.